On August 11, 2021, Lotus Health Group Company closed the transaction. The company issued 413,977,186 shares at a price of CNY 2.40 per share for gross proceeds of CNY 993,545,246.4. The transaction included participation from Zhoukou Chengtou Investment Co., Ltd. for CNY 399,999,998.40 with a lockup period of 6 months, Chengdu Jiaozi Oriental Investment Development Partnership (Limited Partnership) for CNY 199,999,999.20 with a lockup period of 6 months, returning investor, Wuhu Liantai Investment Management Center (Limited Partnership) for CNY 100,800,000 with a lockup period of 18 months, ChangAn Fund Management Co.,Ltd for CNY 39,999,998.40 with a lockup period of 6 months, Boshen No. 27 Securities Investment Private Equity Fund, a fund managed by Shanghai Boshen Investment Center (Limited Partnership) for CNY 39,999,998.40 with a lockup period of 6 months, Liu Baojun for CNY 39,999,998.40 with a lockup period of 6 months, Zhao Yongcun for CNY 37,999,999.20 with a lockup period of 6 months, Guotai Junan Securities Co., Ltd. for CNY 30,000,000 with a lockup period of 6 months, Tao Wentao for CNY 30,000,000 with a lockup period of 6 months, Xue Xiaohua for CNY 30,000,000 with a lockup period of 6 months, Caitong Fund Management Co., Ltd. for CNY 21,000,000 with a lockup period of 6 months, UBS (China) Limited for CNY 19,999,999.20 with a lockup period of 6 months, Xu Yongcai for CNY 3,745,255.20 with a lockup period of 6 months.

The company paid issuance costs of CNY 17,642,470 in the transaction.